Menu Search
Equities

Curvebeam AI Ltd

CRVAF:PKC

Curvebeam AI Ltd

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded5.23k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 06 2024 13:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Curvebeam AI Ltd is engaged in the research, design, and manufacturing of cone beam computed tomography (CT) imaging systems for the orthopedic specialties. The Company is engaged in providing point-of-care diagnostic cone beam CT imaging solutions with artificial intelligence (AI) and deep learning AI (DLAI). Its product categories include orthopedics and bone health. Its orthopedics products include HiRise, LineUP, pedCAT Premium, pedCAT, InReach, and CubeVue Software. Its bone health products include InReach HR-pQCT, and OSSView. HiRise is a bilateral, weight bearing CT imaging of the entire lower extremities including hips/pelvis, distal upper extremities. LineUP is a bilateral, weight bearing CT imaging of the distal lower extremities and distal upper extremities. InReach HR-pQCT is a high resolution peripheral quantitative CT (HR-pQCT) imaging system designed for the point-of-care. OssView Bone Fragility software analyzes HR-pQCT images to measure the bone microarchitecture.

  • Revenue in AUD (TTM)6.53m
  • Net income in AUD-23.10m
  • Incorporated2009
  • Employees50.00
  • Location
    Curvebeam AI Ltd2800 Bronze Dr, Suite 110HATFIELD 19440United StatesUSA
  • Phone+1 (267) 483-8081
  • Websitehttps://curvebeamai.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.